Advancing Inclusive Research^® (AIR) is an innovative cross-functional approach taken to increase representation of under-studied and underrepresented patients in clinical research. We are actively designing studies to learn new insights and build a knowledge base for underrepresented communities. Key inclusive studies include:

• CHIMES: Despite making up almost 20% of the MS population⁴, Black and Hispanic / Latino people living with the disease are vastly underrepresented in clinical research. This has limited the collection of complete and accurate data on the disease biology of MS in these populations. To address this, we conducted a Phase IV study of Black/African American and Hispanic/Latino patients with relapsing-remitting multiple sclerosis.
• CHIMES exceeded its target, enrolling 150 Black or Hispanic/Latino patients more than two months ahead of schedule.
• ELEVATUM: This Phase IV study assessed treatment response in patient groups who are disproportionately affected by diabetes and at higher risk of developing diabetic macular edema, a leading cause of vision loss, and who had not been adequately represented in previous clinical studies.
• ELEVATUM enrolled 124 patients one month ahead of schedule.
• CATORI: Many American Indians and Alaska Natives do not receive specialty care though they have a higher rate of long-term diseases, many of which are preventable or manageable. We launched this observational study to learn why and reveal further insights about the healthcare experiences of this population.

Partnering with the Advancing Inclusive Research Site Alliance, we have published multiple award-winning educational videos to provide easy-to-understand information about clinical studies and the importance of inclusive clinical research.

Learn more by viewing our Clinical Trials YouTube Playlist.

Clinical research studies help us develop medicines that are safe and effective. These brochures provide easy-to-understand information on clinical research studies with emphasis on population representation and inclusion. These materials were co-created with sites in the Advancing Inclusive Research Site Alliance.

Genentech works with diverse teams of experts who strategize on how to reach more representative patient populations.

• The External Council for Advancing Inclusive Research
  Includes physician thought leaders, academic researchers, and patient advocates with expertise in oncology, ophthalmology and neuroscience clinical care, research and genomics.
• Advancing Inclusive Research Site Alliance Champions
  Includes oncology and ophthalmology clinical investigators, physicians, researchers and community educators.

Collectively, these experts understand the needs of their communities and know how to build trust with patients. By identifying best practices with these partners, we are able to amplify learnings within all our studies.

At Roche and Genentech, we believe that improving health outcomes for all patients is core to our mission, and we are committed to being industry leaders in delivering improved health outcomes for all.

In the increasingly diverse world around us, the time is now for research and clinical development to ensure greater inclusion of patients from different backgrounds in support of optimizing health outcomes for all patients worldwide.

Because disease outcomes and drug responses can vary across populations, research must include patients who are from populations representative of those who experience disease. We are deeply committed to addressing barriers to clinical trial participation, diversifying genetic data for scientific discovery, and increasing access to innovative diagnostic and therapeutic solutions, by advancing inclusive research.

By building trusted partnerships with patients, providers and across the healthcare ecosystem, we can collectively combine scientific advances, new technologies and real-world data to drive scientific innovation and create new standards for inclusive research.

As we strive to deliver more patient benefit, we are passionately addressing healthcare disparities in order to deliver ever more personalized healthcare solutions for all patients.